IHEEZO

Coverage without compromise

Sterile,
single-use

Uniform
coverage^5,6

Antiseptic
support⁷

Viscosity Matters

Novel low-viscosity gel for uniform coverage without antiseptic interference^5-7

Avoids excess residue, supporting antiseptic effectiveness⁷
Reduces reliance on external applicators, minimizing potential ocular surface irritation^5,6
Smooth, uniform coverage without excessive pooling or the need for redistribution^5,6

Up to

less viscous than other FDA-approved topical ocular anesthetic gels.^1,2,5,6

Viscosity Comparisons*

*The comparison chart is only comparing the viscosity of preparations. This chart is not intended to compare safety or efficacy.

A randomized in-vivo study demonstrated IHEEZO^® did not act as a barrier to the bactericidal actions of povidone-iodine 5%⁷

A recent study comparing IHEEZO and tetracaine ophthalmic solution 0.5% found that preservative-free chloroprocaine ophthalmic gel 3% achieved a 79.3% reduction in colony-forming units (CFU) versus 72.1% with tetracaine, demonstrating that IHEEZO does not inhibit the effectiveness of povidone-iodine.⁷

Rapid Results, Real Comfort²

IHEEZO works quickly to provide consistent, patient-reported pain reduction¹

View Efficacy data

Key Safety Data

Sterile, single-use, and built for safety¹

An established safety profile comparable to other topical ocular anesthetics¹

IHEEZO is preservative-free and delivered in a sterile, single-use ampule for added patient safety.² Single-use packaging may decrease the risk of infection and medication errors.⁸

Treatment-Emergent Adverse Events by Organ Class¹

Two mild TEAEs were reported in the Tetracaine 0.5% group, while none were reported in the Chloroprocaine 3% Gel group.

Rapid metabolism

Chloroprocaine is a rapidly metabolized local anesthetic. In vitro half-life for IHEEZO is approximately 25 seconds.¹

Rapid plasma degradation

The rapid plasma degradation of chloroprocaine greatly reduces the risk of systemic toxicity. In a clinical trial, chloroprocaine was undetectable in any plasma sample of any patient.¹

Get started with IHEEZO^®

Explore Options

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

IHEEZO should not be injected or intraocularly administered.

Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.

Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.

Do not touch the dropper tip to any surface as this may contaminate the gel.

IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.

The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.

You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about IHEEZO, please see the full Prescribing Information.